Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N, Watkin S, Larsen F. Harlin M, et al. Among authors: larsen f. CNS Drugs. 2023 Apr;37(4):337-350. doi: 10.1007/s40263-023-00996-8. Epub 2023 Mar 24. CNS Drugs. 2023. PMID: 36961650 Free PMC article. Clinical Trial.
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
McIntyre RS, Such P, Yildirim M, Madera-McDonough J, Zhang Z, Larsen F, Harlin M. McIntyre RS, et al. Among authors: larsen f. Curr Med Res Opin. 2023 Jul;39(7):1021-1030. doi: 10.1080/03007995.2023.2219155. Epub 2023 Jun 9. Curr Med Res Opin. 2023. PMID: 37272079 Clinical Trial.
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
Citrome L, Such P, Yildirim M, Madera-McDonough J, Beckham C, Zhang Z, Larsen F, Harlin M. Citrome L, et al. Among authors: larsen f. J Clin Psychiatry. 2023 Sep 4;84(5):23m14873. doi: 10.4088/JCP.23m14873. J Clin Psychiatry. 2023. PMID: 37672016 Free article. Clinical Trial.
Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.
Buur L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, Kallunki P, Ditlevsen DK, Sørensen MH, Meulien D. Buur L, et al. Among authors: larsen f. Mov Disord. 2024 Mar 17. doi: 10.1002/mds.29784. Online ahead of print. Mov Disord. 2024. PMID: 38494847
Age of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium.
Larsen FK, Baksh RA, McGlinchey E, Langballe EM, Benejam B, Beresford-Webb J, McCarron M, Coppus A, Falquero S, Fortea J, Levin J, Loosli SV, Mark R, Rebillat AS, Zaman S, Strydom A. Larsen FK, et al. Alzheimers Dement. 2024 May;20(5):3270-3280. doi: 10.1002/alz.13779. Epub 2024 Mar 20. Alzheimers Dement. 2024. PMID: 38506627 Free PMC article.
793 results